Log In
Print
BCIQ
Print
Print this Print this
 

Lymphoseek, tilmanocept

Also known as: 99mTc-DTPA (formerly Mannosyl-Dextran)

  Manage Alerts
Collapse Summary General Information
Company Navidea Biopharmaceuticals Inc.
DescriptionRadioisotope technetium-99m that binds to mannose binding receptor (MBR; CD206) proteins on the surface of immune cells
Molecular Target Mannose binding receptor (MBR) (CD206)
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect lymph nodes for biopsy around tumors; Detect sentinel lymph nodes in patients with head and neck cancer; Detect sentinel lymph nodes in patients with melanoma, breast cancer or squamous cell carcinoma of the oral cavity; Detect sentinel lymph nodes in patients with squamous cell carcinoma of the head and neck (SCCHN); Identification of the sentinel lymph node (SLN); Identify excised lymph nodes in patients with known melanoma and breast cancer; Identify lymph nodes draining from a primary tumor; Identify sentinel lymph nodes in melanoma patients; Intraoperative lymph node mapping in patients with colorectal cancer; Intraoperative lymph node mapping in patients with melanoma or breast cancer
Regulatory Designation

U.S. - Fast Track (Detect sentinel lymph nodes in patients with head and neck cancer);
U.S. - Orphan Drug (Detect sentinel lymph nodes in patients with head and neck cancer);
U.S. - Priority Review (Detect sentinel lymph nodes in patients with head and neck cancer)

Partner

Cardinal Health Inc.; Hainan Sinotau Pharmaceutical Co. Ltd; Norgine B.V.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today